Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Refractory B-Cell Lymphoma Clinical Trial

Official title:
An Observational Clinical Study on the Safety and Efficacy of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma

Status Not yet recruiting

Clinical Trial Summary

This is a single-centre, single-arm and open-label study to investigate the safety and efficacy of anti CD19/CD22 CAR NK cells in patients with relapsed refractory B cell lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03824964
Study type	Interventional
Source	Allife Medical Science and Technology Co., Ltd.
Contact
Status	Not yet recruiting
Phase	Early Phase 1
Start date	February 1, 2019
Completion date	January 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06158386` - Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma	Phase 2
Recruiting	`NCT05003141` - PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies	Phase 1
Recruiting	`NCT04300998` - Study of CAR-T Therapy in Older Patients
Not yet recruiting	`NCT03692767` - Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Early Phase 1
Not yet recruiting	`NCT03690310` - Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Early Phase 1
Recruiting	`NCT06378190` - Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New Technology	Phase 1/Phase 2
Not yet recruiting	`NCT03824951` - Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma	Early Phase 1